Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer-Reference-Cited by-同舟云学术

Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer

Published:2019-04 Issue:5 Volume:7 Page:935-938
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Kim Dohhyung¹^ORCID

Affiliation:

1. Division of Pulmonary Medicine and Allergy Department of Internal Medicine Dankook University Hospital Dankook University College of Medicine Cheonan Korea

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.2122

Reference18 articles.

1. Posterior reversible encephalopathy syndrome

2. Posterior Reversible Encephalopathy Syndrome: A Review

3. Clinical assessment of immune-related adverse events

4. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer

5. Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports;Cancers;2024-05-16

2. Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors;Current Neurology and Neuroscience Reports;2024-03-18

3. Neuro-ophthalmic complications of modern anti-cancer drugs;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-02-12

4. Nivolumab-Induced PRES (Posterior Reversible Encephalopathy Syndrome);Cureus;2023-06-16

5. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management;Revue Neurologique;2023-06